AAP
TEVA icon

Arax Advisory Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Arax Advisory Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$738K Buy
21,768
+11,074
+104% +$369K ﹤0.01% 1382
2026
Q1 		$322K Buy
10,694
+1,005
+10% +$32.3K 0.01% 841
2025
Q4 		$302K Sell
9,689
-7,910
-45% -$195K 0.01% 824
2025
Q3 		$356K Buy
17,599
+16,583
+1,632% +$291K 0.01% 1039
2025
Q2 		$85.4K Hold
1,016
– – ﹤0.01% 1007
2025
Q1 		$15.6K Buy
1,016
+16
+2% +$286 ﹤0.01% 1406
2024
Q4 		$22K Hold
1,000
– – ﹤0.01% 1176
2024
Q3 		$18K Hold
1,000
– – ﹤0.01% 1131
2024
Q2 		$16.3K Buy
+1,000
New +$15.4K ﹤0.01% 1048

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Arax Advisory Partners's TEVA Position: Q2 2026 in Review

Arax Advisory Partners increased its Teva Pharmaceuticals (TEVA) stake by 104% in Q2 2026, buying an estimated $369K and bringing the position to 21,768 shares worth $738K. The position accounts for ﹤0.01% of the portfolio, ranked #1382.

Arax Advisory Partners first reported a position in TEVA in Q2 2024 and has held it in 9 quarters since. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Arax Advisory Partners held 21,768 shares of Teva Pharmaceuticals worth $738K as of Q2 2026.
  • Arax Advisory Partners bought 11,074 Teva Pharmaceuticals shares in Q2 2026, an estimated $369K.
  • Teva Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #1382 holding.
  • Arax Advisory Partners first reported a position in Teva Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.